

WHOWEARE

Established in 1948, Hemas Holdings is one of Sri Lankan's leading conglomerate with focused interest in Consumer and Healthcare.

Listed in the Colombo Stock Exchange Hemas has presence in Sri Lanka and Bangladesh, bringing healthful living to life through its offerings.

75
Years in Operation

93_{mn}
Market
Capitalisation

35%
Free Float

USD
258_{mn}
Total Assets

Long-term
Fitch Rating

>5k Employees

Key Milestones

1948 "Established Hemas Drugs Pvt Ltd"

2003 "IPO on the Colombo Stock Exchange"

2007 "Extended operations into Hospital Space"

2013 "Acquired leading Pharmaceutical Manufacturing firm – JL Morison"

2018 "Acquired Sri Lanka's Largest Stationery Brand- Atlas"

IMPLICATIONS OF KEY MACRO ECONOMIC PARAMETERS ON HHL



Surge In Inflation

"Change buying consumer with reduced disposable patterns income"

57.2% **CCPI**

59.2% **NCPI**

YoY change (Dec 2021 vs Dec 2022)



Interest Rates

"6x YoY growth in Group finance cost for the quarter due to inflationary pressure and increased working capital to ensure product availability"

> 1,986 bps AWPI R

YoY change (Dec 2021 vs Dec 2022)



Depreciation of LKR

"Input cost inflation with increased cost on imported raw materials and pharmaceuticals"

81.2%

YoY change (Dec 2021 vs Dec 2022)



Tax Reforms

"Increased corporate tax and the oneoff impact of deferred tax coupled with the domino effect on consumer demand and consumption-driven growth"

30%

Corporate Tax rate

1.2 Mn

Personal tax relief threshold



Global Commodity prices

"Prices of key commodities saw a declining momentum which was not fully translated to the consumer business due to forex impact and the lag effect"

-26.0% Palm Oil

-8.9% Crude Oil

"India and the Paris Club have given assurance to the IMF on providing debt restructuring support to Sri Lanka. The country is discussing with other official bilateral creditors to obtain similar assurances"



Sound Corporate Governance Structure with an Independent Board



Strong balance sheet with a net gearing of 25%



Diversified and competent Leadership Team

KEY STRENGTHS



Long-Term Rating of AAA (lka)' Stable Outlook



Presence in key defensive segments Healthcare and Consumer



Strong value creating partnerships with internal and external stakeholders 4

Corporate Governance





BOM (Board of Management)

Consists of the senior leadership team of 9 members - MDs of our 5 major businesses and 4 leaders from Corporate Office. BOM is responsible for formulation and implementation of Group strategic plan and ensures that the Group works in a collaborative and high-performance manner not-withstanding the circumstances and challenges the Group faces.



The Board

Takes overall responsibility for the performance and affairs of the Company and the Group



Board Subcommittees

Ensures in-depth focus on delegated matters



Group CEO

Leads the Executive Management team. Responsible for strategy development, implementation and Group performance

Board Composition

- Independent directors
- Non-Executive Directors (including Chairman)
- Executive Directors





0

Independence



of the board is independent

Gender



90%: 10%

Board Size



Board size promoting accountability and encouraging healthy, constructive debate and decision-making, while meeting regulatory requirements

Expertise

Experienced Board, combining knowledge and skills relevant to the Group





STRATEGIC BUILDING BLOCKS





Accelerate current business efforts to drive higher value in core business



New within the core and Adjacencies

Capturing new revenue streams to further strengthen the core and adjacencies



New business and Internationalisation

Explore attractive opportunities in new spaces and international markets



Efficiencies

Efficiency and productivity to further enhance capacity and improve growth

Our Strategic Building Blocks – Q2 FY 2022-23



MORE FROM THE CORE

- HPC SL: Launched lower grammage products to capture consumers purchasing smaller packs due to the current economic conditions (e.g 'Kumarika' and 'Dandex' launched an 80ml refill pack, 'Velvet Cutie' 70g soap and 'Baby Cheramy' budget pack)
- Bangladesh: Introduced 'Eva' and 'Kumarika' 150ml variant and 'Actisef mini'
 30 g variant to capture consumers driven by price in the current inflationary environment.
- Double-digit growth reported in exports in Q3 FY23 vs Q3 last year.
- Atlas: 'Light a Future' initiative commenced its donation drive.
- Pharma: Launched over 40 new pharmaceutical and surgical products. New pharmaceutical products covered respiratory and wellness spaces whilst surgical products were focused on in-patient care.



NEW WITHIN THE CORE

• **Pharma**: Signed an agreement with a principal operating in the orthopedic space providing state of the art treatments focusing on bone related surgeries.



- Atlas: Exports displayed progress in expanding to new geographical markets.
- Hemas ventured into the food industry with the recent launch of 'Tasty Country Flakers', a wholesome breakfast cereal made with 100% natural ingredients.



EFFICENCY AND PRODUCTIVITY

- **Hospitals**: Focused on 5S,Kaizen and Lean initiatives as well as methods to improve turn around time in operational processes and surgical procedures.
- HPC SL: Conducted initiatives related to waste reduction.
- Pharma: Focused on route optimisation as a measure to reduce escalating transportation costs experienced at the warehouse.
- Atlas: 3,200+ Lean kaizens implemented. Commenced manufacturing of glue bottles in house as a cost saving measure.

New Product Launches during the Quarter

Home and Personal Care Sri Lanka



'Tasty Country Flakers'

"Made with 100% natural ingredients and free of chemicals, preservatives, artificial flavours, and colours"

'Baby Cheramy' value packs





' Dandex' shampoo refill

'Kumarika' shampoo refill



Home and Personal Care International

'Actisef' Mini – 30g variant






Hair Oil 150 ml variants

FINANCIAL SNAPSHOT


9M CONTRIBUTION TO GROUP




9M Performance FY 23 vs FY22

LKR 81.7 Bn 1 41.6% Revenue













EBIT BY SEGMENT (LKR MN)




FY20 Q3 FY21 Q3 FY22 Q3 FY23 Q3

FY23 Q2


Sector Performance Summary – 9M FY 2022-23









Sector Performance Summary – Q3 FY 2022-23






Continuing Operation EPS and Capital Employed – 9M FY 2022-23







Note

The size of the circle indicates the EBIT values

The 'other segment' includes the corporate office and remaining leisure assets

Consumer Brands




Home and personal care – International


Learning Segment



Consumer Brands



Sector Performance – 9M FY 2022-23



Key Highlights

- Consumers remained price sensitive on the back of multiple tax reforms and inflationary pressure.
- Market witnessed price reductions under declined key commodity prices.
- Despite the high value growth, the industry continued to report double-digit contraction in volume terms.
- Increased competition with all participants being active in the stationery market.
- Soaring inflation, depreciating currency, energy shortage, slowdown of the recovery from the pandemic and poor economic conditions in key export markets adversely impacted the Bangladesh market.

Home and Personal Care – Sri Lanka

Key categories with market leading positions



-23% 9M volume growth

75k+ Direct outlet coverage

9M contribution to consumer revenue

Women to be **Nurturing SL** strengthening family by investing in coming together **Beauty** future-ready bonds through good Yourself for the best care practices passed for baby down Baby Kumarika Clogard Cheramy

Home and Personal Care Sri Lanka: Strong Brand Portfolio











of business - Hemas is among the Top 3 players



#1
In Beauty Soap





In Feminine Care



#2
In Laundry Care



#2
In Oral Care





Beauty Care



Hygiene Care



Female Fragrances



Male Grooming



Shampoo



Presence in all modern trade chains and outlets



of households reached by Hemas brand



Strong 3rd party manufacturing partnerships




Value adding partners including Garnier, L'Oreal and Nivea

Our Consumer Health Brands







UPDATE ON KEY STRATEGIC INITIATIVES

"Premiumisation and expanding into key underpenetrated categories will be the drivers of domestic growth"


Progress update ...

- Beauty Brand 'Vivya' was well received by the market, the business will look into portfolio expansion and increasing reach.
- Male Grooming Following the multiple successful launches, 'Glod' has improved its market share in terms of both value and volumes.
- Diva Power Range(Germ and Colour Guard) has maintained market share amidst the pricing pressure.





Opportunities in Urbanisation and Premiumisation will be the platform to drive growth



Emerging Trends in the Consumer Space

- High focus on health and Transparency.
- Rise in awareness and acceptance in inclusive beauty.
- Increasing demand for male grooming products



Opportunities to capitalise on underpenetrated (less than 45% penetration) emerging categories



7.1% CAGR 2021 -2026



8.6%CAGR



Feminine Hygiene 5.1%CAGR 2022-2027

UPDATE ON KEY STRATEGIC INITIATIVES


"Fine blend of Innovation and the uniqueness of Sri Lanka, where natural ingredients, traditional knowledge, and new technologies drive the future of the beauty market"





Clean beauty that prioritises natural ingredients are a prime aspect in the future of personal care.

Percentage of people who look for products that uses natural ingredients




Global Natural and Organic personal care Market (\$ Bn)





Growing Demand will provide opportunities to cater to premium market segments

% of Consumers willing to pay a premium price for GMO free / Organic / Natural products – By country











COPYRIGHT © 2022 | HEMAS HOLDINGS PLC

Home and Personal Care – International

Geographies
Bangladesh & West Bengal

Key categories
Health soap category—Actisef

Market share in VAHO
(Bangladesh – Q2 FY23 Data)

Retailers reached in Bangladesh

9M contribution to Consumer Brands revenue

Note: VAHO – Value Added Hair Oil, CNO – Coconut Oil

Locally led and localised in Bangladesh

- All products are exclusively designed for Bangladesh.
- Extensive product portfolio with multiple value adding variations targeted for overall wellness, growth and nourishment of hair.
- Local leadership team with 90% local talent.
- 2nd most loved hair oil brand of Bangladesh (Best Brand Awards 2022)



Reach in Bangladesh



Rural penetration by Hemas



Urban penetration of Hemas



of households reached by Hemas



On-shoremanufacturing

Home and Personal Care - Sri Lanka and International

Sri Lanka

Revenue


- Volumes withessed a deciming momentum amidst the inflationary pressure.
- Value for money portfolio was extended to improve affordability.
- Over 10% of YTD revenue from new launches and relaunches.
- Ventured into the food industry with the recent launch of 'Tasty Country Flakers', a wholesome cereal made with natural ingredients.

Profitability

 Increased working capital base and high cost of borrowing adversely impacted the margins.

Outlook

 Exploring opportunities in underpenetrated areas, driving exports and catering into the evolving consumer needs will continue to be the priorities for the Business.



International

Revenue

- With the challenging macro economic conditions, volumes witnessed a double-digit contraction.
- In response to the rising inflation all three key products 'Kumarika', "Eva" and "Actisef" introduced variants at affordable price points.

Profitability

- Profit margins were challenged with the increase in raw material cost and currency devaluation impact.
- Amidst the high inflation, overheads including administration and marketing expenses increased during the period.

Outlook

 High focus on opportunities for growth in Bangladesh by expanding the portfolio in core and adjacent spaces.

Atlas: Where We Inspire the Next Generation to Unleash Their Potential

"We provide tools, content and experiences which will enable the next generation to unleash their potential"



KIDS

Catering to all stationery and back-to-school needs



Young/Adults

Growing market due to greater focus on higher education &stationery as a lifestyle product



Office

Providing one stop professional stationery solutions



Atlas

- Our story started over 60 years ago in September 1959
- Business continues to drive the lean manufacturing agenda
- Focuses on brand building and premiumisation and on extending to emerging markets.

Creating A Purpose Based Brand Experience







Assisting Learning

Carefully Crafted Brand Portfolio in Line with Growth Areas















Atlas was crowned the Local Brand of the year at SLIM Brand Excellence Awards 2022

UPDATE ON KEY STRATEGIC INITIATIVES

"Learning Segment: Widening the business scope to expand growth and reach"



Progress update ...

- Learn platform targeting grade 5 students has gained traction.
- On going discussions with global partners to secure contracts for exports



Explore opportunities to expand geographical reach via partnering with global players



Middle east Stationery market will grow at a CAGR of 1.3% to reach \$ 321.6 Mn in 2025

Gulf

32% of the growth will originate from UAE

High growth expectations in underpenetrated regional Markets



Worlds second largest out of school rates with over 20 Mn Children not receiving formal education



Only 64% of children are completing Bangladesh secondary education

Global Stationery Market (\$ Billion)



Sources: GlobeNewswire, statista.com, UNISEF



Develop in the digital space with the curriculum development and lesson planning platform - LEARN



"Highest computer literacy rate in Sri Lanka of 67.9% is witnessed among those between the ages of 15-19 years"



Learning Segment

6 Key categories



High Efficiency and productivity through lean initiatives



Market leader in key product categories

50k Outlet coverage across Sri Lanka

26% 9M Contribution to Consumer Brands revenue



Revenue

- Atlas maintained its market leading position despite the increased competition.
- Building up to the back-to-school season, revenue witnessed a significant improvement during the quarter.

Profitability

 Increased borrowings to fund the broadened working capital base at high interest ratesimposed pressure on margins.

Outlook

- Sustain the market leading position with innovative product offerings.
- Focus on growing the export portfolio in regional and other markets.

THE GROWING ECONOMY OF BANGLADESH

India

urma)

Mymensingh

Bangladesh

India

Rangpur

€ Dhaka

Bhutan

\$ **460.8** Bn

GDP 2022

\$ 2,730GDP Per Capita.

9.2% Inflation 2022 Aug.

165 Mn+
Population 2022

 GDP Growth Forecasts

 FY 2024-25
 8.0%

 FY 2023-24
 7.8%

 FY 2022-23
 7.2%

37.5 %
Gross Government Debt % of GDP 2022

\$36.5 Bn

Forex Reserve 2022 Sep.

"Bangladesh has a remarkable story of poverty reduction and development"

Promising Macro economic factors to support growth and expansion

FDI friendly tax laws and incentives

Access to labour at attractive prices

Strategic Location for land and sea trade

FTAs with several international organisations

Low penetration in many key categories

Urbanisation and digitalisation driving premiumisation

Healthcare Sector


Pharmaceutical Import, Marketing and Distribution

Pharmaceutical Manufacturing


Hospitals



Healthcare Sector



Sector Performance – 9M FY 2022-23



Key Highlights

- Sri Lanka continued to rely on multiple donations and credit lines to finance the medical needs of the country.
- Increasing tendency for outward migration by young specialists will impose challenges in the long-run.
- Deteriorating purchasing power and product unavailability resulted in overall volumes to contract in the pharmaceutical market.
- Increase in buying frequency was witnessed specially for essential medication.
- Equitable allocation mechanism for the Government buy back volumes is still unseen.

Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing

Pharmaceutical Import, Marketing, and Distribution

50+ Principals

Private market leader In import and distribution



Distributes: Pharmaceuticals, Surgicals & Diagnostics, leading consumer healthcare products



Beheth 2.0

A digital portal to assist pharmacists serve patients better



Island wide product availability (within 24 hours)



110+

Distributors

3,100+ Pharmacies

Pharmaceutical Manufacturing

70+

Formulations - Manufacturing



1st and largest EU GMP compliant general oral solid and liquid dosage manufacturing plant in Sri Lanka



Strong Portfolio of Branded Generics used in key NCD spaces



5Bn tablets and **2Mn** liquids Morison capacity per annum



#1 in volume

Highest selling pharmaceutical in the country MSJI Ascorbic Acid 100mg 1000s



Partnering with **3** Global pharma Principals for contract manufacturing

Morison Plant and Key Highlights



NPD focused separate manufacturing line consisting of advanced technology, Partnerships with International CRO



Minimum human interaction using latest global technology 1st zero liquid discharge effluent treatment plant in Sri Lanka



Built in SLINTEC park in collaboration with SLINTEC for research



Contract manufacturing opportunities lined up for leading global brands



Largest supplier of bulk generics to the private market in volumes



Branded Generics- Focus on premium quality at affordable prices

UPDATE ON KEY STRATEGIC INITIATIVES "Homagama Factory"

"Homagama factory: Annual capacity of 5 Bn tablets and 2 Mn litres of liquids, which is equivalent to 40 % of the national annual general OSD demand in Sri Lanka"



- Commercial production of the Homagama plant was commenced in Q1 FY23
- Over 5 New products are in the pipeline to cater to key therapeutic segments including cardio, diabetic and vitamins.
- Utilisation levels of the factory are still in the single digit range however, progressing well to achieve 25% target by end 2024.
- Competition from local manufacturers is lower due to Morison having the advantage of completion of a fully fledged factory prior to the economic crisis.



Opportunities to enter into global supply chain via contract manufacturing due to Sri Lanka's proximity to India and availability of infrastructure and know how

Key Export Markets for Sri Lanka













Global Pharmaceutical Market (\$ Trillion)





Expand and grow in Private Branded Generic Space by focusing on Non-Communicable Diseases (NCDs)

- Sri Lanka has the fastest growing population in South Asia, and it is projected that by 2030, one in five Sri Lankans will be over the age of 60 (majority women)
- NCDs cause over 80% of deaths in Sri Lanka. More than a quarter of Sri Lankan's are overweight, and one in four adults consume tobacco.


Branded Generics Market in Sri Lanka (Rs Bn)





Sources: UNFPA, WHO 2020

Pharmaceutical Import, Marketing, Distribution and Pharmaceutical Manufacturing



Revenue

- Pharmaceutical arm continued to ensure product availability liaising with principals, banks and other stakeholders.
- Increased performance of the '*Morison*' Branded Generics portfolio coupled with price adjustments drove the revenue growth of the Pharmaceutical arm.

Profitability

- Currency devaluation impact and the finance cost-imposed pressure on margins despite the growth in revenue.
- Multiple restructuring and efficiency improvement projects were carried out to increase the operational savviness of the Manufacturing business.

Outlook

- In line with Morison's purpose "Making Premium Healthcare Affordable", extending the branded generics portfolio to create a "Sri Lankan Brand" will be the key priority for the business.
- Aaccelerating contract manufacturing, expanding into export markets and improved research and development efforts will contribute to the long-term value creation.

The first Internationally accredited hospitals chain in Sri Lanka by the Australian Council on Healthcare Standards International

Hemas Hospitals Highlights

Centers of Excellence:

- Maternity unit (461 baby deliveries in Oct
 Dec 22)
- Urology and Kidney Care unit (27 Kidney Transplants in Oct - Dec 22)
- Gastrointestinal unit (GI) (44 Admissions in Oct - Dec 22)
- Orthopedic unit (194 Admissions in Oct-Dec 22)
- Dialysis unit (1,991 Dialyses in Oct Dec 22)





"The first Internationally accredited hospitals chain in Sri Lanka by the Australian Council on Healthcare Standards International (ACHSI)"

Aim To Become Sri Lanka's First SMART & LEAN Hospital Chain International Patient Centre One Stop Services for International Patients Operates Home Care and Primary Care Centres

Q3 FY 2022-23 Performance



1,600+ PCR Tests



2,600+
Surgeries



64% Occupancy



4,600+
Admissions



152k+
Outpatients

We have a widespread Lab Network

Lab Network Highlights

Centers of Excellence:

- Main Lab Services to Hospitals (8 B2B Labs +3 B2B CCs)
- Outer Labs services across the country (14 Labs)
- Collection centers across the country (14 CCs)
- PCR lab service
- 2400+ test portfolio
- Home mobile service
- Digitally connected lab network and patient portal

Q3 FY 2022-23 Performance



266k+ Test volumes



2k+GP Referrals



5k+Rapid Antigen Tests (RAT)




New Locations

ISO 15189: 2012

Accredited laboratory chain in Sri Lanka by SLAB

Aims to become the No.02 Laboratory Chain in Sri Lanka by 2024

50+ Labs & Collection Centers across the Country



UPDATE ON KEY STRATEGIC INITIATIVES

"Capacity expansion via opportunities for organic and inorganic growth"



Progress update ...

- Renal Unit: Gaining traction, performed 100+ Kidney transplants during the year.
- Cosmetic Centre: Continue to perform over 500 procedures per quarter.


COPYRIGHT © 2022 | HEMAS HOLDINGS PLC



Building depth and scale of identified anchor and super specialties


Urology: The prevalence of Chronic Kidney Disease is 15.1–22.9% in farming districts.

Cardiovascular: Incidence of coronary artery disease (CAD) in Sri Lanka has doubled over the past two decades



Private sector to bridge the gap between limited infrastructure in Government hospitals and growing demand for medical care

Average waiting time at a National Hospital for elective cardiothoracic operation is over 9.4 months, 5.7% will die while waiting for their operation.



Hospitals

170+

Beds

60% Ho

Hospital occupancy



First hospital in Sri Lanka to implement fully fledged EHR system



2

50+

Hospitals

Lab network

14%

9M contribution to Healthcare revenue



Revenue

 Core businesses (excluding COVID-19 related revenue) witnessed a growth of over 30% with high improved medical admissions.

Profitability

 Lower COVID-19 related revenue streams and reduced medical admissions adversely impacted the margins for the quarter.

Outlook

 Hospitals business will prioritise selected anchor and super specialties while improving the footfall and efficiency of the core businesses.

IP revenue mix	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23
	52%	50%	47%	49%	54%

Mobility Sector




Maritime






Mobility Sector



Sector Performance – 9M FY 2022-23



Key Highlights

- YTD total throughput and transhipment volumes at Port of Colombo declined by over 7 % due to slow down in the global economy and reduced demand in key destinations.
- Aviation industry is returning to normalcy with multiple airlines which discontinued operations over the past few months recommencing operations under improved business conditions.
- Amidst the high yields, the Passenger sector witnessed an increased demand for both inbound and outbound travel.
- Decline in EBITDA is due to the one-off disposal gain recorded in Q3 FY22 with the divestment of the logistic operation.

Mobility Sector

2

Shipping line – Evergreen line & Far Shipping



250 k+ TEUs

9M FY 23

545

Vessel sailing
1H FY 23



Emirates

General Sales Agent for over 20 years

20%

Air cargo market share

19%

Passenger Market share

"Offering a Full Spectrum of End-to-end Services across Land, Sea and Air"

Facilitating over 1000+ supply chains

Emirates cargo: Average daily freight capacity of 75 tons.
Emirates Passenger:
Connecting Sri Lanka to over 154 destinations across the alobe

Represents the leading feeder operator to the East Coast of India and Bay of Bengal

Representations





EVERGREEN LINE



GROUP ENVIRONMENTAL AGENDA

Hemas will play a leading role in helping sustain and nurture all that is Sri Lankan





Roof Mounted Solar

25%

Offsetting Group Electricity Consumption





Addressing Marine Pollution

27,000+ KG

To Date Plastic Collection (9 Locations)

SUPPORTING OUR COMMUNITIES

Creating an inclusive world by eliminating inequality and creating a social security net



5,000+ Free Testing





Training Sessions

Tackling diabetes in sri lanka

Providing essential learning tool packs

Empowering women and providing her solutions to aspire for more



100 Teachers Trained




Early childhood care and development

Creating a safer world

Tackling period poverty

Sustainability Performance - Q3 2021-22 vs Q3 2022-23





Values of Fines for Non-Compliance with Laws and Regulations in the Social Economic Area

NONE



Total Work-Related Injury Rate (per 100 employee) none

NONE



Training Hours and Development

13,601 Hours

9%



Gender Diversity

(female employees) 29.7%

0.3%

FOCUS AREAS

Short -Term

Grow Market Share

Develop value creating products to cater to the evolving needs of the customers

Expanding the regional footprint with high focus in Bangladesh

Maintaining an optimum liquidity position

Invest in optimising resources and upscaling talent



Mid - Long Term

Acquisitions/expansion in consumer and healthcare

Grow in the Learning space by moving into adjacent spaces

Develop a strong private brand of generics under Morison

Establish presence in new international markets

SHORT TERM OUTLOOK AND STRATEGIES ON NAVIGATING THE ECONOMIC CRISIS

- Leverage on the strong relationships with external and internal stakeholders to minimise the possible adverse impact on businesses due to temporary political and economic headwinds.
- Implement strategies to maintain optimum levels of working capital by securing bank facilities, renegotiating
 with suppliers and aligning production schedules with planned power cuts.
- Cater to the evolving needs of the consumers and introduce value for money alternatives.
- Further strengthen the relationships with banks, regulatory bodies, venders etc to improve the resilience of the value chains across the business eco system.
- Continue to invest in acquiring, retaining and upscaling talent culture with greater autonomy and flexibility.

